Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a sell rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

A number of other research firms have also recently issued reports on ENTA. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Wednesday, September 23rd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Enanta Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA opened at $12.60 on Friday. The company has a market capitalization of $366.91 million, a PE ratio of -5.23 and a beta of 0.96. The company’s 50 day moving average price is $13.12 and its 200 day moving average price is $13.28. Enanta Pharmaceuticals has a 52 week low of $10.20 and a 52 week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.The company had revenue of $14.36 million during the quarter, compared to analysts’ expectations of $16.76 million. On average, equities analysts forecast that Enanta Pharmaceuticals will post -2.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Large investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP bought a new position in Enanta Pharmaceuticals during the fourth quarter valued at about $36,000. Legal & General Group Plc bought a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter worth about $41,000. Clearstead Trust LLC bought a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter worth about $74,000. Kingsview Wealth Management LLC acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at about $168,000. Finally, Bank of America Corp DE acquired a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at about $314,000. 94.99% of the stock is currently owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and liver diseases. The company’s research and development activities have included treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), SARS-CoV-2 and other infectious diseases.

Enanta’s most notable commercial contribution is glecaprevir, a direct-acting antiviral developed in collaboration with AbbVie and included in the Mavyret and Maviret treatment for chronic hepatitis C virus (HCV) infection.